<DOC>
	<DOCNO>NCT01088711</DOCNO>
	<brief_summary>This study test safety tolerability omarigliptin . It hypothesize administration once-weekly omarigliptin obese otherwise healthy participant , obese participant Type 2 diabetes ( T2D ) sufficiently safe well tolerated permit continue clinical investigation .</brief_summary>
	<brief_title>Evaluation Omarigliptin ( MK-3102 ) Obese Participants Participants With Type 2 Diabetes ( MK-3102-004 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>obese ( body mass index [ BMI ] ≥30 kg/m² ≤40 kg/m² ) male participant female participant nonchildbearing potential diagnose T2D ( Panel B ) actively participate weight loss program history clinicallysignificant disease ( T2D ) history cancer estimate creatinine clearance ≤60 mL/min unable refrain anticipates use prescription nonprescription medication consumes excessive amount alcohol caffeine participate previous omarigliptin study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Type 2 diabetes ( T2D )</keyword>
</DOC>